SonoCloud

Low Intensity Contact Ultrasound Implant 

The SonoCloud® Device

The SonoCloud® is an implantable medical device, which is fixed to the skull. Since the device must be MRI compatible, the device does not contain any integrated power source. The upper face, which is in contact with the underside of the skin, contains a connection channel that receives a bipolar needle which is introduced through the skin at each use. The bottom face, which is in contact with the dura mater and brain, consists of a transducer that emits ultrasound energy to open the blood-brain barrier.

The SonoCloud® device is powered and controlled by an external generator that verifies the quality of the electrical connection, delivers radio-frequency energy to power the device, and saves the entire procedure sequence.

Illustration of the top face of the SonoCloud®, which accepts a power source temporarily through a transcutaneous needle connection. The connection can be easily made by a nurse during each BBB opening procedure.

SonoCloud111

  • unnamed-2
    unnamed-3

     

  • News CarThera

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    Read more
    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.

    Read more
    03.07.2017
    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

    Read more
    All the news